Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocuphire Pharma Inc OCUP

Healthcare
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1a... see more

Recent & Breaking News (NDAQ:OCUP)

First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

GlobeNewswire 8 days ago

Ocuphire Announces the U.S. Commercial Launch of RYZUMVl(TM) (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

GlobeNewswire April 1, 2024

Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update

GlobeNewswire March 8, 2024

Ocuphire Pharma to Present in the BIO CEO & Investor Conference

GlobeNewswire February 23, 2024

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 15, 2024

Ocuphire Pharma Strengthens Leadership Team with Key Appointments

GlobeNewswire February 14, 2024

Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference

GlobeNewswire February 5, 2024

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 24, 2024

Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions

GlobeNewswire January 4, 2024

Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII

GlobeNewswire November 30, 2023

Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 27, 2023

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

GlobeNewswire November 27, 2023

Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update

GlobeNewswire November 13, 2023

Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy

GlobeNewswire November 2, 2023

Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 1, 2023

Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director

GlobeNewswire November 1, 2023

Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase

GlobeNewswire October 26, 2023

Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October

GlobeNewswire October 6, 2023

Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI(TM) (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents

GlobeNewswire September 27, 2023

Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl(TM) (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents

PR Newswire September 27, 2023